Related Experiment Video
Updated: Jul 20, 2026

Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
Bjørg Johanne Warø1,2, Jan O Aasly1,2
1Department of Neuroscience Norwegian University of Science and Technology Trondheim Norway.
Objectives:
To compare the risk of non-skin cancer in LRRK2 mutation carriers and individuals with idiopathic Parkinson's disease (iPD), explore the age at which LRRK2 mutation carriers have cancer compared to iPD subjects, and clarify whether certain cancers are more closely associated with the LRRK2 mutation than iPD.
Materials And Methods:
Demographic data and cancer outcomes from 830 iPD patients and 103 LRRK2 mutation carriers (27 with PD) were retrospectively collected. Oncologic data were obtained from the Cancer Registry of Norway and included cancer type and age at cancer. All study participants were of Norwegian ethnicity.
Results:
LRRK2 mutation carriers have increased risk of non-skin cancer compared with iPD subjects (OR 2.09; 95% CI 1.16-3.77; p = .015). A significant association was found between the mutation and breast cancer in women (OR 4.58; 95% CI 1.45-14.51; p = .010). No other associations between harboring a LRRK2 mutation and specific cancer types were uncovered.
Conclusion:
LRRK2 mutation carriers have an increased risk of non-skin cancer compared with iPD subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women. The increased risk is likely independent of ethnicity.
More Related Videos
08:55Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
Published on: December 14, 2017
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Related Concept Videos
Neural Regulation
Lysosomal Hydrolases
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology